Gamgertamig

安格妥米单抗

Report date: 2026/05/25 20:02:40

Base Information

Drug NameGamgertamig
Drug Alias NameCM-336注射液CM-336OM336
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-BCMAAnti-CD3
TargetsB-cell maturation proteinT cell surface glycoprotein CD3
Therapy Area/IndicationsEvans syndromeCytopeniaAmyloidosis +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesKeymed Biosciences Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesKangnuoya Biomedical Technology Co LtdOuro Medicines LlcChengdu Kangnuoxing Biopharma Inc +[8] 
Inactive CompaniesN/A
Active IndicationsEvans syndromeCytopeniaAmyloidosis +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A